Chronic lymphocytic leukemia in a young population

Affiliations


Abstract

Introduction: Chronic lymphocytic leukemia (CLL) is uncommon in the Middle East. There is limited data on the prognosis and of CLL in this region.

Methods: This was a retrospective study (2009-2020) of consecutively diagnosed patients with CLL at Kuwait Cancer Center. The diagnosis, prognosis, treatment indication, response criteria, and adverse events were recorded per International Workshop on Chronic Lymphocytic Leukemia guidelines.

Results: A total of 219 patients with CLL were enrolled in the study. The crude annual incidence is 0.4 per 100,000. The median follow-up was 120 months. The median age at diagnosis was 59 years, and 32 % of patients with CLL were ≤ 55 years of age. Prognostic fluorescence in situ hybridization data were available in 213 cases. del (13q14/13q34) was found in 80 (31 %) cases, del (11q) in 23 (10.7 %) cases, del (17p) in 11 (5.16 %) cases, and trisomy 12 in 46 (21.5 %) cases. IGHV mutation status was available in 92 cases, 45 of which (48.9) were mutated and 47 (51.1 %) of which were not. The median progression-free survival (PFS) for the entire cohort was 178 months [95 % CI: 145-NE].· The median OS was 203 months [95 % CI: 145-NE]. The median PFS for the IGHV mutated cases was not reached [95 % CI: 178 - NE]; while the median PFS for the unmutated CLL cases was 24 months [95 % CI: 124 - NE].

Conclusion: CLL is a rare hematological malignancy in the Middle East. Our CLL cohort is younger and expresses less del13q, but has similar rates of IGHV mutations.

Keywords: Cytogenetics; Epidemiology; IGHV status; Kuwait; Prognosis.


Similar articles

Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J.Leuk Lymphoma. 2018 Jan;59(1):59-68. doi: 10.1080/10428194.2017.1323271. Epub 2017 Jun 22.PMID: 28641468 Free PMC article.

Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.

Spunarova M, Tom N, Pavlova S, Mraz M, Brychtova Y, Doubek M, Panovska A, Skuhrova Francova H, Brzobohata A, Pospisilova S, Mayer J, Trbusek M.Leuk Res. 2019 Jun;81:75-81. doi: 10.1016/j.leukres.2019.04.015. Epub 2019 Apr 25.PMID: 31054420

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Gladstone DE, Blackford A, Cho E, Swinnen L, Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade J, Jones RJ.Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):132-7. doi: 10.1016/j.clml.2011.12.005. Epub 2012 Jan 28.PMID: 22285608 Free PMC article.

Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.

Zenz T, Döhner H, Stilgenbauer S.Best Pract Res Clin Haematol. 2007 Sep;20(3):439-53. doi: 10.1016/j.beha.2007.02.006.PMID: 17707832 Review.

Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.

Stilgenbauer S, Bullinger L, Lichter P, Döhner H; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia.Leukemia. 2002 Jun;16(6):993-1007. doi: 10.1038/sj.leu.2402537.PMID: 12040431 Review.


Cited by

The Mysterious Actor-γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL).

Zarobkiewicz MK, Bojarska-Junak AA.Cells. 2022 Feb 14;11(4):661. doi: 10.3390/cells11040661.PMID: 35203309 Free PMC article. Review.


References

https://pubmed.ncbi.nlm.nih.gov/